AMG 337
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms
Trial Timeline
Feb 1, 2014 → Oct 1, 2016
NCT ID
NCT02016534About AMG 337
AMG 337 is a phase 2 stage product being developed by Amgen for Stomach Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT02016534. Target conditions include Stomach Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02096666 | Phase 1/2 | Completed |
| NCT02016534 | Phase 2 | Terminated |
| NCT01253707 | Phase 1 | Completed |
Competing Products
20 competing products in Stomach Neoplasms